MedtechInsight.com

Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home

Online Report Subscribers, Click Here

Pricing and Ordering Information

U.S. Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems Market
Report #A458 - May 2011
118 Pages – 31 Exhibits – 7 Company Profiles

Benign prostatic hyperplasia (BPH), or the noncancerous enlargement of the prostate gland, is a common condition associated with aging. While the prostate grows throughout a man’s lifetime, bothersome growth typically begins at age 40, and by approximately age 60 more than half of men will have experienced at least some symptoms of BPH; by age 80, up to 80% to 90% of men become symptomatic. It is estimated that nearly 15 million men in the United States and 30 million men worldwide experience symptoms of BPH; of this number, an estimated 25% require pharmaceutical or surgical treatment. Due to the aging of the population, the number of men with the condition is expected to follow an upward trend. This presents a significant unmet need for minimally invasive or less invasive BPH therapy as a less costly, more tolerable, and comparatively safe and effective alternative to drugs and invasive surgery, which carry greater risk of undesirable or significant side effects and complications.

While current economic conditions continue to restrain market growth, the U.S. market for minimally invasive bariatric surgical devices is expected to exhibit relatively good growth over the next 5 years. Valued at an estimated $147.5 million in 2010, the U.S. minimally invasive benign prostatic hyperplasia therapy systems market is expected to increase at a compound annual rate of 2.4%, with sales reaching more than $166 million in 2015. The largest segment, laser BPH therapy, is expected to drive market growth over the forecast period—expanding at a comparatively higher rate of 4.6%—at the expense of minimally invasive office-based therapies.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include transurethral microwave thermotherapy (TUMT); transurethral needle ablation (TUNA); holmium laser ablation of the prostate (HoLAP); photoselective vaporization of the prostate (PVP), or Greenlight Laser Therapy; transurethral resection of the prostate (TURP); and other energy-based technologies.

Ordering Information

Title	Report#	Publication Date	List Price
U.S. Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems Market	A458	May 2011	$3,750
Order Online: Single User only (Please call for corporate subscription pricing)			PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i. Causes

ii. Symptoms

iii. Diagnosis

iv. Treatment

a. Prescription Drugs

b. Minimally Invasive Therapy

c. Surgery

d. Stents

v. Minimally Invasive Benign Prostatic Therapy Systems Market

a. Procedure Volumes Forecast

b. Market Forecast

vi. Methodology

Exhibit ES-1: The Prostate and Urine Flow

Exhibit ES-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia

Exhibit ES-3: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2010-2015

Exhibit ES-4: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015

1. CLINICAL OVERVIEW OF BENIGN PROTATIC HYPERPLASIA

1.1 Causes

1.2 Symptoms

1.3 Diagnosis

1.4 Treatment

1.4.1 Prescription Drugs

1.4.2 Minimally Invasive Therapy

1.4.3 Surgery

1.4.4 Stents

Exhibit 1-1: The Prostate and Urine Flow

Exhibit 1-2: Commonly Prescribed Drugs for Benign Prostatic Hyperplasia

2. MINIMALLY INVASIVE BENIGN PROSTATIC HYPERPLASIA THERAPY SYSTEMS

2.1 Transurethral Microwave Thermotherapy

2.1.1 CoreTherm: ProstaLund Operations

2.1.2 Prolieve System: Boston Scientific

2.1.3 Cooled ThermoTherapy: Urologix

2.1.4 TherMatrx Office Thermo Therapy: American Medical Systems

2.2 Transurethral Needle Ablation: Medtronic

2.3 Laser- and Other Energy-Based Therapies

2.3.1 Holmium Laser Ablation/Enucleation of the Prostate

2.3.1.1 VersaPulse PowerSuite: Lumenis

2.3.2 Photoselective Vaporization of the Prostate

2.3.2.1 GreenLight Laser Therapy: American Medical Systems

2.3.3 Other Laser-Based Technologies

2.3.3.1 EVOLVE Laser System: Biolitec

2.3.3.2 Odyssey Holmium Laser: Convergent Laser Technologies

2.3.3.3 PlasmaButton Vaporization Therapy: Gyrus ACMI/ Olympus America/Olympus

2.3.3.4 Thulium Lasers: HealthTronics/Endo Pharmaceuticals

2.3.4 Other Energy-Based Technologies

2.3.4.1 Aptocine: Light Sciences Oncology

2.4 Prostatic Stents

2.4.1 The Spanner Prostatic Stent: AbbeyMoor Medical

2.4.2 CoreFlow Soft Stent: ProstaLund Operations

2.4.3 UroLume Urethral Stent: American Medical Systems

2.5 Market Analysis

2.5.1 Procedure Volumes Forecast

2.5.2 Market Forecast

2.5.2.1 Market Drivers

2.5.2.2 Market Limiters

2.6 Competitive Analysis

Exhibit 2-1: Advantages and Disadvantages of Minimally Invasive Therapy for Benign Prostatic Hyperplasia

Exhibit 2-2: 2011, Selected Microwave- and Radiofrequency-Based Benign Prostatic Hyperplasia Therapy Systems

Exhibit 2-3: The CoreTherm System

Exhibit 2-4: Five-Year Clinical Comparison of Symptomatic Reduction in Benign Prostatic Hyperplasia Using the CoreTherm System and Competitive Treatments

Exhibit 2-5: The Schelin Catheter

Exhibit 2-6: The CoolWave and Targis Systems

Exhibit 2-7: The Cooled ThermCath Advance Catheter

Exhibit 2-8: Cooled ThermoTherapy, Selected Five-Year Clinical Trial Results

Exhibit 2-9: Comparison of Cooled ThermoTherapy with Drug Therapy, Selected Clinical Results

Exhibit 2-10: The Prostiva Radiofrequency Therapy System

Exhibit 2-11: Holmium Laser Ablation of the Prostate Using the VersaPulse PowerSuite Laser System

Exhibit 2-12: Selected Advantages of Holmium Laser Ablation Using the VersaPulse PowerSuite Compared with Photoselective Vaporization Using the GreenLight PV

Exhibit 2-13: The GreenLight High Performance System

Exhibit 2-14: The GreenLight Xcelerated Performance System

Exhibit 2-15: The MoXy Liquid Cooled Fiber

Exhibit 2-16: The EVOLVE Laser System

Exhibit 2-17: PlasmaButton Vaporization Therapy

Exhibit 2-18: Aptocine’s Effects on Tumor Cells, and Selected Benefits of Aptocine Treatment

Exhibit 2-19: The Spanner Prostatic Stent

Exhibit 2-20: The CoreFlow Soft Stent

Exhibit 2-21: Benefits of the UroLume Urethral Stent

Exhibit 2-22: Transurethral Resection of the Prostate and Minimally Invasive Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2010-2015

Exhibit 2-23: Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2010-2015

Exhibit 2-24: 2010, Benign Prostatic Hyperplasia Laser Therapy Systems Market, Share by Supplier

Exhibit 2-25: 2010, Transurethral Microwave Thermotherapy and Transurethral Needle Ablation Systems Market, Share by Supplier

3. COMPANY PROFILES

3.1 American Medical Systems, Inc.

3.2 Boston Scientific Corporation

3.3 Lumenis LTD

3.4 Medtronic, Inc.

3.5 Olympus America/Olympus Corporation

3.6 ProstaLund Operations AB

3.7 Urologix, Inc. PENDIX: COMPANYLISTIN

To order reports or obtain information about special pre-publication offers from within the U.S., contact reports@elsevier.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.